



ITW

Docket No. PRD-2110-USANP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : MacDonald et al. Confirmation No.: 1638  
Appln. No. : 10/667,096  
Filed : September 18, 2003  
Title : METHODS OF INCREASING PLATELET AND HEMATOPOIETIC  
STEM CELL PRODUCTION  
Art Unit : 1647  
Examiner : Bridget E. Bunner

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

November 16, 2007

(Date of Deposit)

Laura A. Donnelly  
(Name of applicant, assignee, or Registered Representative)

/Laura A. Donnelly/

(Signature)

November 16, 2007

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CROSS-REFERENCE TO RELATED APPLICATIONS AND  
SUBMISSION OF DOCUMENTS REGARDING SAME

Dear Sir:

Applicants submit this CROSS-REFERENCE TO RELATED APPLICATIONS AND  
SUBMISSION OF DOCUMENTS REGARDING SAME document to draw the Office's  
attention to applications that could be deemed to contain related subject matter:

| Attorney Docket No. (Assignee)                                 | Application Serial No.         | Title  | Continuity   | Status  | Representative Claim  |
|--|--------------------------------|--|--|---|---|
| SPC5199USDIV1<br>(SmithKline Beecham Corporation) <sup>1</sup> | 11/610,226<br>(filed 12/13/06) | Peptides and compounds that bind to a receptor | DIV of 11/254,419 (10/20/05); CON of 10/083,768 (02/27/02) (U.S. Patent No. 7,091,311); CON of 09/549,090 (04/13/00) (U.S. Patent No. 6,465,430); CON of 08/973,225 (12/04/97) (U.S. Patent No. 6,083,913); 371 of PCT/US96/09623 (06/07/96) | Examiner not assigned<br>Awaiting first Office Action                     | 19. A compound that binds to a thrombopoietin receptor, wherein said compound comprises X9 X8 G X1 X2 X3 X4 X5 X6 X7, where X1 is P; X2 is T; X3 is L; X4 is R; X5 is Q; X6 is selected from the group consisting of W (Trp), L-Trp, D-Trp, L-1-Nal, D-1-Nal, L-2-Nal, D-2-Nal, L-(Benzothienyl)-alanine, DL-5-Me-Trp, DL-1-Me-Trp, DL-6-F-Trp, DL-5-F-Trp, DL-5-Br-Trp and L-Tic; X7 is L; X8 is E; X9 is I. |
| TDP5001USNP<br>(Ortho-McNeil Pharmaceutical, Inc.)             | 10/918,561<br>(08/13/04)       | Peptides and compounds that bind to a receptor | 60/498,740<br>(08/28/03)   | Assigned to Examiner Julie Ha<br>Response to Office Action filed 09/24/07 | 50. A peptide compound that binds to a thrombopoietin receptor, wherein said peptide compound comprises I E G P T L R Q (2-Nal) L A A R (Sar) (SEQ ID NO:7), wherein (2-Nal) is $\beta$ -(2-naphthyl)alanine and (Sar) is sarcosine   |
| TDP5001USCIP1  | 11/200,416                     | Peptides and                                   | CIP of   | Assigned to   | 50. A method for  |

<sup>1</sup> Rights to this application were obtained via a license agreement.

| Attorney Docket No. (Assignee)              | Application Serial No. | Title   | Continuity                                   | Status  | Representative Claim  |
|---|------------------------|---|--|---|---|
| (Ortho-McNeil Pharmaceutical, Inc.)         | (08/09/05)             | compounds that bind to a receptor   | 10/918,561 (08/13/04); 60/498,740 (08/28/03) | Examiner Julie Ha<br>Awaiting first Office Action | treating a patient suffering from a disorder that is susceptible to treatment with a thrombopoietin agonist, comprising administering to the patient a therapeutically effective dose or amount of a peptide compound comprising the following sequence: (H-IEGPTLRQ(2-Nal)LAARX <sub>10</sub> ) <sub>2</sub> K-NH <sub>2</sub> wherein X <sub>10</sub> is sarcosine. |
| PRD2222USNP (Janssen Pharmaceutica, N.V.)   | 11/181,049 (07/14/05)  | Use of TPO mimetic compounds in the treatment of anemia                                 | 60/601,921 (08/16/04)                        | Assigned to Examiner Julie Ha<br>Abandoned        | 1. A method of preventing the development of anemia following treatment comprising administering an effective amount of a TPO mimetic compound to a subject in need thereof.  |
| PRD2222USCIP1 (Janssen Pharmaceutica, N.V.) | 11/354,065 (02/14/06)  | Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia | 11/181,049 (07/14/05); 60/601,921 (08/16/04) | Awaiting Examination                              | 12. A method of preventing the development of anemia following treatment comprising administering an effective amount of a TPO peptide compound to a subject in need  |

| Attorney Docket No. (Assignee)                      | Application Serial No.   | Title   | Continuity   | Status  | Representative Claim  |
|---|--------------------------|---|--|---|---|
|   |                          |   |  |   | thereof, said TPO peptide compound comprising the following structure:<br>I E G P T L R Q<br>(2-Nal) L A A R<br>(Sar) (SEQ ID NO:5).  |
| PRD2110USANP<br>(Ortho-McNeil Pharmaceutical, Inc.) | 10/667,096<br>(09/18/03) | Methods of increasing platelet and hematopoietic stem cell production | 60/411,779<br>(09/18/02) and<br>60/411,700<br>(09/18/02) | Assigned to Examiner<br>Bridget E. Brunner<br><br>RCE and Amendment filed<br>10/26/07 | 2. A method of providing hematopoietic stem cells to a subject comprising the steps of: administering a thrombopoietin (TPO) mimetic compound to a subject to increase stem cells in said subject; harvesting one or more of the stem cells; treating said subject with a bone marrow ablative treatment; and transplanting the harvested stem cells into the subject, wherein the TPO mimetic compound has the following sequence:<br>I E G P T L R Q<br>(2-Nal) L A A R<br>X <sub>10</sub> , wherein (2-Nal) is β-(2-naphthyl)alanine and X <sub>10</sub> is Sar. |

The documents listed in the table below are submitted for the Office's review.

| Application Serial No. (Attorney Docket No.) | Documents Submitted   |
|--|---|
| 11/610,226<br>(SPC5199USDIV1)                | <p>Preliminary Amendment, filed 12/13/06</p> <p>Information Disclosure Statement, filed 12/13/06</p> <p>Submission of Form PTO-1449 and Notice of References Cited by the Examiner, filed 12/13/06</p>  |
| 10/918,561<br>(TDP5001USNP)                  | <p>Amendment in Response to Notice Under 37 CFR §§ 1.821-1.825, filed 02/28/05</p> <p>Information Disclosure Statement, filed 06/10/05</p> <p>Preliminary Amendment, filed 01/27/06</p> <p>Requirement for Restriction, dated 01/11/07</p> <p>Response to Requirement for Restriction, filed 02/05/07</p> <p>First Supplemental Information Disclosure Statement, filed 03/09/07</p> <p>Office Action, dated 03/30/07</p> <p>Second Supplemental Information Disclosure Statement, filed 08/06/07</p> <p>Submission of Written Opinion, filed 08/21/07</p> <p>Amendment, filed 09/24/07</p> |
| 11/200,416<br>(TDP5001USCIP1)                | <p>Preliminary Amendment, filed 02/10/06</p> <p>Information Disclosure Statement, filed 08/06/07</p> <p>Submission of Written Opinion, filed 08/21/07</p> <p>Notice to Comply with Requirements for</p>   |

| Application Serial No. (Attorney Docket No.) | Documents Submitted  |
|--|--|
|  | <p>Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated 09/18/07</p> <p>Amendment in Response to Notice Under CFR §§ 1.821-1.825, filed 10/17/07</p>   |
| 11/181,049<br>(PRD2222USNP)                  | <p>Information Disclosure Statement, filed 03/09/07</p> <p>Office Action, dated 05/21/07</p> <p>First Supplemental Information Disclosure Statement, filed 07/24/07</p> <p>Submission of Written Opinion, filed 08/21/07</p> <p>Express Abandonment, filed 09/21/07</p> <p>Notice of Abandonment, dated 10/22/07</p>   |
| 11/354,065<br>(PRD2222USCIP1)                | <p>Information Disclosure Statement, filed 07/24/07</p> <p>Submission of Written Opinion, filed 08/01/07</p> <p>Response to Notice to File Corrected Application Papers, filed 10/01/07</p> <p>Amendment, filed 10/01/07</p>   |
| 10/667,096<br>(PRD2110USANP)                 | <p>Information Disclosure Statement, filed 01/23/04</p> <p>First Supplemental Information Disclosure Statement, filed 03/24/06</p> <p>Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated 01/26/06</p> <p>Amendment in Response to Notice Under CFR §§ 1.821-1.825, filed 02/24/06</p> <p>Requirement for Restriction, dated April 19,</p> |

| Application Serial No. (Attorney Docket No.) | Documents Submitted  |
|--|--|
|  | <p>2006</p> <p>Second Supplemental Information Disclosure Statement, filed 05/18/06</p> <p>Amendment, filed 05/18/06</p> <p>Office Action, dated 08/03/06</p> <p>Amendment, filed 02/01/07</p> <p>Notice of Non-Compliant Amendment, dated February 16, 2007</p> <p>Amendment, filed 03/12/07</p> <p>Third Supplemental Information Disclosure Statement, filed 03/12/07</p> <p>Final Office Action, dated 05/08/07</p> <p>Request for Continued Examination and Amendment, filed 10/26/07</p> |

By making this submission, Applicants have endeavored to provide the Office with sufficient information regarding the related cases for the Office's use. Should the Office require anything further, it is invited to contact Applicants' representative at the telephone number below.

Respectfully submitted,

*/Laura A. Donnelly/*

By: \_\_\_\_\_

Laura A. Donnelly  
Reg. No. 38,435

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
Dated: November 16, 2007



SPC-5199-USDIV1  
Appln. No. 11/610,226